Insmed (INSM) – Research Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Insmed (NASDAQ: INSM) in the last few weeks:

• 7/12/2024 – Insmed had its price target raised by analysts at Morgan Stanley from $60.00 to $85.00. They now have an “overweight” rating on the stock.
• 7/10/2024 – Insmed had its price target raised by analysts at The Goldman Sachs Group, Inc. from $74.00 to $102.00. They now have a “buy” rating on the stock.
• 7/9/2024 – Insmed had its price target raised by analysts at Guggenheim from $70.00 to $95.00. They now have a “buy” rating on the stock.
• 7/8/2024 – Insmed had its price target raised by analysts at HC Wainwright from $70.00 to $90.00. They now have a “buy” rating on the stock.
• 7/5/2024 – Insmed had its “buy” rating reaffirmed by analysts at Bank of America Co.. They now have a $83.00 price target on the stock.
• 7/2/2024 – Insmed had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
• 7/1/2024 – Insmed had its price target raised by analysts at Truist Financial Co. from $68.00 to $88.00. They now have a “buy” rating on the stock.
• 6/28/2024 – Insmed had its price target raised by analysts at Bank of America Co. from $62.00 to $83.00. They now have a “buy” rating on the stock.
• 6/21/2024 – Insmed had its price target raised by analysts at Evercore ISI from $42.00 to $75.00. They now have an “outperform” rating on the stock.
• 6/20/2024 – Insmed had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
• 6/20/2024 – Insmed had its price target raised by analysts at JPMorgan Chase & Co. from $55.00 to $72.00. They now have an “overweight” rating on the stock.
• 6/7/2024 – Insmed had its price target raised by analysts at Mizuho from $36.00 to $82.00. They now have a “buy” rating on the stock.
• 5/31/2024 – Insmed had its price target raised by analysts at Stifel Nicolaus from $39.00 to $67.00. They now have a “buy” rating on the stock.
• 5/29/2024 – Insmed had its price target raised by analysts at Wells Fargo & Company from $55.00 to $77.00. They now have an “overweight” rating on the stock.
• 5/29/2024 – Insmed had its price target raised by analysts at JPMorgan Chase & Co. from $36.00 to $55.00. They now have an “overweight” rating on the stock.
• 5/29/2024 – Insmed had its price target raised by analysts at Barclays PLC from $40.00 to $63.00. They now have an “overweight” rating on the stock.
• 5/29/2024 – Insmed had its price target raised by analysts at TD Cowen from $45.00 to $67.00. They now have a “buy” rating on the stock.
• 5/29/2024 – Insmed had its price target raised by analysts at The Goldman Sachs Group, Inc. from $49.00 to $74.00. They now have a “buy” rating on the stock.
• 5/29/2024 – Insmed had its price target raised by analysts at UBS Group AG from $46.00 to $58.00. They now have a “buy” rating on the stock.
• 5/29/2024 – Insmed had its price target raised by analysts at Truist Financial Co. from $48.00 to $68.00. They now have a “buy” rating on the stock.
• 5/29/2024 – Insmed had its price target raised by analysts at HC Wainwright from $52.00 to $70.00. They now have a “buy” rating on the stock.
• 5/28/2024 – Insmed had its “buy” rating reaffirmed by analysts at Bank of America Co.. They now have a $40.00 price target on the stock.

Insmed Stock Up 0.1 %

Shares of NASDAQ:INSM traded up $0.07 during trading on Thursday, hitting $74.50. The stock had a trading volume of 1,716,709 shares, compared to its average volume of 2,555,528. Insmed Incorporated has a 12-month low of $20.28 and a 12-month high of $78.87. The stock has a market capitalization of $11.07 billion, a price-to-earnings ratio of -14.24 and a beta of 1.16. The stock has a 50-day simple moving average of $59.39 and a two-hundred day simple moving average of $38.51.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.16. The company had revenue of $75.50 million for the quarter, compared to analysts’ expectations of $77.76 million. The firm’s revenue was up 15.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.17) earnings per share. As a group, sell-side analysts forecast that Insmed Incorporated will post -4.71 earnings per share for the current year.

Insider Activity at Insmed

In related news, CEO William Lewis sold 22,198 shares of Insmed stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $25.52, for a total transaction of $566,492.96. Following the completion of the transaction, the chief executive officer now directly owns 384,125 shares in the company, valued at $9,802,870. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Insmed news, CEO William Lewis sold 22,198 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $25.52, for a total value of $566,492.96. Following the sale, the chief executive officer now directly owns 384,125 shares of the company’s stock, valued at $9,802,870. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Sara Bonstein sold 11,088 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $25.32, for a total value of $280,748.16. Following the completion of the sale, the chief financial officer now directly owns 117,481 shares in the company, valued at $2,974,618.92. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 295,842 shares of company stock worth $13,762,062. 4.60% of the stock is owned by corporate insiders.

Institutional Trading of Insmed

Several institutional investors have recently bought and sold shares of INSM. International Assets Investment Management LLC acquired a new stake in shares of Insmed in the fourth quarter worth approximately $25,000. EntryPoint Capital LLC acquired a new stake in shares of Insmed in the first quarter worth approximately $33,000. Fidelis Capital Partners LLC acquired a new stake in shares of Insmed in the first quarter worth approximately $34,000. First Horizon Advisors Inc. boosted its stake in shares of Insmed by 83.4% in the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 287 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Insmed in the first quarter worth approximately $59,000.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.